文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

基于供者可及性的减低强度造血干细胞移植治疗50-75岁晚期MDS的生物分配试验

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.
PubMed 文献 · J Clin Oncol · 2021-06-09

这项多中心生物分配试验纳入384例50-75岁中危-2或高危原发MDS受试者,按90天内是否找到匹配供者分为供者组和无供者组,比较减低强度HCT与去甲基化治疗或最佳支持治疗。供者组3年总生存率47.9%,无供者组26.6%,绝对差异21.3%,无白血病生存亦更优。

要点

  • 有匹配供者并接受减低强度HCT的老年高危MDS患者3年总生存率显著优于无供者组。
  • 3年总生存率供者组47.9% vs 无供者组26.6%,绝对差异21.3%(95%CI 10.2-31.8)。
  • 3年无白血病生存供者组35.8% vs 无供者组20.6%(P=.003)。

核心结论

  • 在50-75岁高危MDS患者中,找到匹配供者并接受减低强度HCT者较无供者者观察到显著生存优势。
  • HCT应作为适合的老年高危MDS患者管理计划中的组成部分。

研究设计与样本

  • 多中心生物分配试验,比较减低强度HCT与去甲基化治疗或最佳支持治疗。
  • 按研究注册后90天内是否有匹配供者分为供者组和无供者组,主要终点为3年总生存概率。

主要发现

  • 供者组存活者中位随访34.2个月(范围2.3-38),无供者组26.9个月(范围2.4-37.2)。
  • 意向性治疗分析中,供者组3年调整总生存率47.9%(95%CI 41.3-54.1),无供者组26.6%(95%CI 18.4-35.6),P=.0001。
  • 绝对差异21.3%(95%CI 10.2-31.8)。
  • 供者组3年无白血病生存率35.8%(95%CI 29.8-41.8),无供者组20.6%(95%CI 13.3-29.1),P=.003。
  • 生存获益在所有 examined 亚组中均可见。

临床怎么用

  • 对适合的老年高危MDS患者,应评估匹配供者并在管理计划中纳入减低强度HCT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to older patients. The relative benefits of HCT over non-HCT therapy in older patients with higher-risk MDS have not been defined. METHODS: We conducted a multicenter biologic assignment trial comparing reduced-intensity HCT to hypomethylating therapy or best supportive care in subjects 50-75 years of age with intermediate-2 or high-risk de novo MDS. The primary outcome was overall survival probability at 3 years. Between January 2014 and November 2018, we enrolled 384 subjects at 34 centers. Subjects were assigned to the Donor or No-Donor arms according to the availability of a matched donor within 90 days of study registration. RESULTS: The median follow-up time for surviving subjects was 34.2 months (range: 2.3-38 months) in the Donor arm and 26.9 months (range: 2.4-37.2 months) in the No-Donor arm. In an intention-to-treat analysis, the adjusted overall survival rate at 3 years in the Donor arm was 47.9% (95% CI, 41.3 to 54.1) compared with 26.6% (95% CI, 18.4 to 35.6) in the No-Donor arm (P = .0001) with an absolute difference of 21.3% (95% CI, 10.2 to 31.8). Leukemia-free survival at 3 years was greater in the Donor arm (35.8%; 95% CI, 29.8 to 41.8) compared with the No-Donor arm (20.6%; 95% CI, 13.3 to 29.1; P = .003). The survival benefit was seen across all subgroups examined. CONCLUSION: We observed a significant survival advantage in older subjects with higher-risk MDS who have a matched donor identified and underwent reduced-intensity HCT, when compared with those without a donor. HCT should be included as an integral part of MDS management plans in fit older adults with higher-risk MDS.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Nakamura R, Saber W, Martens MJ, et al. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. J Clin Oncol. 2021. PMID: 34106753. doi:10.1200/JCO.20.03380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。